The MIND diet was associated with slower cognitive decline in both Black and white older adults, but relationships appeared ...
The incubator is designed to draw cell and gene therapy researchers and drugmakers to work at the hub, where they can develop ...
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s ...
Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial. Shares in the Anglo-US biotech rose sharply ...
News Medical on MSN11h
Human midbrain organoids: A promising tool in the fight against Parkinson's diseaseAdvancements in organoid technology are crucial for Parkinson's disease research, providing human-relevant models for ...
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...
allowing certain patients with anti-AAV antibodies to still be candidates for CNS-directed gene therapy. "In particular, an AAV2-GAD therapy in Parkinson's disease patients demonstrated that ...
The Michael J. Fox Foundation (MJFF) has launched a major new initiative to rapidly expedite development of therapeutic ...
(Alliance News) - Syncona Ltd on Wednesday noted positive trial results for a portfolio company's gene therapy aimed at treating people with Gaucher's disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback